Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Non-Current Deffered Revenue (2025)

Kiora Pharmaceuticals' Non-Current Deffered Revenue history spans 1 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, changed N/A, while the annual FY2025 figure was $1.2 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $1.2 million in Q4 2025 per KPRX's latest filing, roughly flat from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q2 2025 to a low of $1.2 million in Q2 2025.